BRUNETTI, ORONZO
 Distribuzione geografica
Continente #
NA - Nord America 3.294
EU - Europa 423
AS - Asia 375
OC - Oceania 2
SA - Sud America 1
Totale 4.095
Nazione #
US - Stati Uniti d'America 3.286
SE - Svezia 217
CN - Cina 186
SG - Singapore 131
IT - Italia 52
GB - Regno Unito 45
FR - Francia 29
BE - Belgio 25
VN - Vietnam 24
DE - Germania 19
IN - India 18
FI - Finlandia 11
CZ - Repubblica Ceca 8
CA - Canada 7
IR - Iran 6
TR - Turchia 3
AU - Australia 2
HK - Hong Kong 2
IE - Irlanda 2
JP - Giappone 2
KW - Kuwait 2
UA - Ucraina 2
AL - Albania 1
AT - Austria 1
BG - Bulgaria 1
CH - Svizzera 1
DK - Danimarca 1
ES - Italia 1
KZ - Kazakistan 1
MT - Malta 1
MX - Messico 1
NL - Olanda 1
NO - Norvegia 1
PL - Polonia 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
RU - Federazione Russa 1
Totale 4.095
Città #
Fairfield 519
Chandler 443
Woodbridge 282
Ashburn 275
Seattle 249
Cambridge 220
Houston 210
Nyköping 182
Wilmington 169
Ann Arbor 108
Dearborn 103
Singapore 93
Lawrence 57
Roxbury 55
New York 41
Beijing 38
Des Moines 35
Brooklyn 29
Nanjing 29
Boardman 27
Brussels 24
Dong Ket 24
San Diego 24
Bari 18
Inglewood 15
Hefei 14
Paris 14
Pune 13
Marseille 10
Shanghai 9
Guangzhou 8
London 8
Los Angeles 8
San Mateo 8
Santa Clara 8
Jinan 7
Augusta 6
Brno 6
Edinburgh 6
Helsinki 6
Jacksonville 6
Kilburn 5
Kunming 5
Monmouth Junction 5
Princeton 5
Washington 5
Ardabil 4
Munich 4
New Bedfont 4
Wuhan 4
Zhengzhou 4
Cinisello Balsamo 3
Falls Church 3
Grafing 3
Hounslow 3
Jiaxing 3
Leawood 3
Nanchang 3
Naples 3
Ningbo 3
Norwalk 3
Redwood City 3
Shaoxing 3
Shenyang 3
Toronto 3
Verbania 3
Wenzhou 3
Baotou 2
Bologna 2
Chicago 2
Chiswick 2
Dallas 2
Dublin 2
Fuzhou 2
Hangzhou 2
Hebei 2
Macerata 2
Milan 2
Mohali 2
Montreal 2
Mumbai 2
Ottawa 2
Prescot 2
Rome 2
Salerno 2
Stockholm 2
Tianjin 2
Tokyo 2
Adelaide 1
Amsterdam 1
Antwerp 1
Asunción 1
Belgrade 1
Bend 1
Bradford 1
Böblingen 1
Chengdu 1
Copenhagen 1
Fiorano Modenese 1
Foggia 1
Totale 3.553
Nome #
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma 186
Angiogenesis in adenosquamous cancer of pancreas 124
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 117
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 113
Targeting angiogenesis in biliary tract cancers: An open option 111
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells 111
Strategies to improve cancer immune checkpoint inhibitors efficacy, other than abscopal effect: A systematic review 111
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 103
Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma 100
CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer 99
Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review 95
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 93
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 93
Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma 93
Fisiologia V Ed. 92
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma 92
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 92
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 91
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 87
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 85
Bone metastases in biliary cancers: A multicenter retrospective survey 83
Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review 82
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 82
null 81
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 81
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy 79
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 77
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib 75
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 75
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 73
Management of patients with end-stage renal disease undergoing chemotherapy: Recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN) 71
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 70
Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer 69
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 69
null 67
Immunotherapy for colorectal cancer: where are we heading? 67
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 66
Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets 65
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 62
null 61
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 57
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials 51
COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients? 48
Immune system and bone microenvironment: rationale for targeted cancer therapies 48
Basics and frontiers on pancreatic cancer for radiation oncology: Target delineation, SBRT, SIB technique, MRgRT, particle therapy, immunotherapy and clinical guidelines 46
Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: Evidence evaluation and recommendations by the italian association of medical oncology (AIOM) 46
The latest findings of PD-1/PD-L1 inhibitor application in gynecologic cancers 41
Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies 39
Expression and characterization of a novel recombinant cytotoxin II from Naja naja oxiana venom: A potential treatment for breast cancer 39
Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection 38
Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma: Could Surgery Represent a Therapeutic Option? 38
Cytotoxic t-lymphocyte antigen-4 in colorectal cancer: Another therapeutic side of capecitabine 35
NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer 32
Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma? 31
Bone metastases in hepatocellular carcinoma: an emerging issue 30
A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery 30
Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis 27
On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents 25
Paraneoplastic focal segmental glomerulosclerosis in sarcomatoid renal cell cancer. 24
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 23
The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead 22
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? 4
Totale 4.317
Categoria #
all - tutte 21.913
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.913


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.097 0 0 0 0 206 174 160 180 187 76 68 46
2020/2021936 41 71 97 148 89 70 72 76 45 87 75 65
2021/2022509 42 19 13 15 20 45 17 30 37 46 68 157
2022/2023929 104 155 85 75 85 95 15 113 140 5 40 17
2023/2024324 19 59 15 28 33 95 7 9 3 7 3 46
2024/2025240 53 11 85 51 40 0 0 0 0 0 0 0
Totale 4.317